Privia Health Group, Inc. (PRVA) stock intrinsic value fair value estimate & owner earnings analysis

Privia Health runs a physician-enablement platform. It supplies technology, billing, administrative and population-health services to independent doctors, who practice through Privia-affiliated medical groups. At the end of 2025 that meant 5,380 providers in more than 1,300 locations, a presence in 24 states and the District of Columbia, and about 5.8 million patients. Roughly 1.5 million of them are "attributed lives" in value-based contracts: about 910,000 commercial, 212,000 Medicare Advantage, 298,000 Medicare Shared Savings or Maryland primary-care program and 120,000 Medicaid. Revenue was $2.12 billion in 2025, up 22% from $1.74 billion, coming from fee-for-service visits, capitated payments and shared savings from lowering the cost of care. Most of that revenue is passed straight to the physicians as provider expense ($1.66 billion), so the company keeps only a thin slice. What we count as earnings. We measure the cash the business generates for shareholders: operating cash flow, less the swing in working capital, less stock-based compensation (a real cost, because it dilutes owners), less maintenance capital spending, which is tiny for this asset-light company. Working capital is stripped out because Privia holds large balances owed to physicians ("provider liability", up $65.6 million in 2025) that flow through operating cash flow but are timing items, not profit. On that basis owner earnings were $0.38 per share in 2025, $0.22 in 2024 and $0.28 in 2023. 2022 was slightly negative (-$0.13) and 2021 deeply negative (-$2.11) because of $253.5 million of stock awards tied to the April 2021 IPO. We measure the business from 2023, after those one-time awards and the post-IPO step-up in stock compensation had settled, and use the median of 2023 to 2025, $0.28 per share (about $35 million a year). Stock compensation has kept rising ($37 million in 2023 to $71 million in 2025), which is why owner earnings are a small fraction of reported operating cash flow of $163 million. Amortization of acquired intangibles ($9.2 million in 2025) is a non-cash add-back; we reflect the decay of acquired relationships in the growth path rather than in the earnings level. Interest income on the $480 million of cash ($9.7 million in 2025) is part of the cash stream, though much of that cash is owed to physicians in the normal course. Growth check. Owner earnings rose about 71% from 2024 to 2025 ($0.22 to $0.38), but that jump is measured from the weakest of the three recent years, so the base case does not extrapolate it and starts at just 6%, below the trailing rate. Base case: $4.37 per share. Owner earnings start at $0.28 and grow 6% a year for five years and 3% a year for the next five. The credited growth is the continuation of a pattern that is already proven: implemented providers grew 11.2% in 2024 and 12.3% in 2025, and the Evolent accountable-care business acquired in December 2025 already brings over 120,000 attributed lives. We discount that pattern heavily because stock compensation absorbs much of the gain and margins are thin. We do not credit margin expansion, a shift to higher-risk contracts, new markets or further acquisitions, since none of these is contracted. After year ten we hold earnings flat for five years and then fade to zero over ten more, since the network of affiliated practices is what persists, while nothing we can name shows the shared-savings economics lasting beyond that. Bear case: $1.13 per share. Value-based revenue relies on management's estimates of shared savings and per-patient revenue (shared savings rose $55.6 million in 2025), and earnings are a thin margin on $2.1 billion of revenue: a small reversal in medical costs or in government program terms erases most of it. 2022 already showed owner earnings turning negative once stock compensation is counted. The bear case assumes owner earnings of $0.12 per share, flat for ten years, then fading to zero over ten years. Bull case: $6.67 per share. Owner earnings return to the 2025 level of $0.38, then grow 8% a year for five years and 4% for five, with the same flat-then-fade tail, if provider growth of 11% to 12% a year continues to translate into cash. What could make this wrong: stock compensation growing faster than cash earnings, changes to Medicare shared-savings rules or Medicare Advantage rates, or the December 2025 acquisition adding lives without adding cash earnings. Some working-capital items, especially provider liability, are large relative to owner earnings, so the result is sensitive to how much of that float is permanent; we treated it as timing and excluded it.